NULIBRY (fosdenopterin), First and Only FDA-Approved Therapy to Reduce the Risk of Mortality in Patients with Molybdenum Cofactor Deficiency Type A, Available Exclusively at Biologics by McKesson

CARY, N.C., April 19, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Origin Biosciences, Inc., an affiliate of BridgeBio Pharma, Inc. (BridgeBio), as the exclusive specialty pharmacy provider for NULIBRYTM (fosdenopterin...
Source: McKesson News - Category: Information Technology Source Type: news